End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
21.61 USD | +4.40% | -4.17% | +107.79% |
May. 16 | HC Wainwright Initiates Dianthus Therapeutics With Buy Rating, $40 Price Target | MT |
May. 10 | Wedbush Adjusts Dianthus Therapeutics' Price Target to $38 From $33, Keeps Outperform Rating | MT |
Business Summary
Number of employees: 53
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Medicines
100.0
%
| 0 | nan % | 3 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | nan % | 3 | 100.0 % | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 29,349,469 | 26,756,178 ( 91.16 %) | 0 | 91.16 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+107.79% | 634M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- DNTH Stock
- Company Dianthus Therapeutics, Inc.